The Tisch Cancer Institute at Mount Sinai is a leader in translating clinical research into cancer immunotherapies for patients. PICI researcher Nina Bhardwaj, MD, PhD, at Mount Sinai is an expert who contributes foundational insights in understanding patient responses to immunotherapy treatments. She closely examines immune behavior to test and develop cancer-curing vaccines. Bhardwaj is instrumental on several PICI research projects and clinical trials, with a focus on prostate and pancreatic cancers. Nina Bhardwaj, MD, PhD | Investigator Related Research Focus Tumor Antigen Discovery: Targeting Cancer Research Project Tumor Neoantigen Selection Alliance (TESLA) Research Update A Collaborative Effort Aims to Change the Future of Patient Care With Cancer Immunotherapy Point of View An Immunologist Breaks Down COVID-19 Announcement A message from PICI: Thank you to those addressing this global pandemic Announcement 2019 Annual Report Cancer Research Heroes, Press Release The Parker Institute for Cancer Immunotherapy Awards $2.75 Million to Support Six Early Career Researchers from Leading Research Institutions Point of View PICI Catalyzes Scientific Innovation Cancer Research Heroes An Insider View of PICI’s Pancreatic Clinical Trial PRINCE
Research Update A Collaborative Effort Aims to Change the Future of Patient Care With Cancer Immunotherapy
Cancer Research Heroes, Press Release The Parker Institute for Cancer Immunotherapy Awards $2.75 Million to Support Six Early Career Researchers from Leading Research Institutions